Implications of Cardiovascular Outcomes Trials in Type 2 Diabetes for Primary Care.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Unger J;Unger J
  • Source:
    The Journal of family practice [J Fam Pract] 2018 Jun; Vol. 67 (6 suppl), pp. S35-S40.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Frontline Medical Communications Country of Publication: United States NLM ID: 7502590 Publication Model: Print Cited Medium: Internet ISSN: 1533-7294 (Electronic) Linking ISSN: 00943509 NLM ISO Abbreviation: J Fam Pract Subsets: MEDLINE
    • Publication Information:
      Publication: Parsippany, NJ : Frontline Medical Communications
      Original Publication: New York, Appleton-Century-Crofts.
    • Subject Terms:
      Cardiovascular Diseases/*etiology ; Diabetes Mellitus, Type 2/*drug therapy ; Dipeptidyl-Peptidase IV Inhibitors/*adverse effects ; Glucagon-Like Peptide-1 Receptor/*agonists ; Hypoglycemic Agents/*adverse effects ; Primary Health Care/*organization & administration; Cardiovascular Diseases/prevention & control ; Clinical Decision-Making ; Clinical Trials as Topic ; Humans ; United States ; United States Food and Drug Administration
    • Abstract:
      Patients with type 2 diabetes (T2D) are at a greater risk of cardiovascular (CV) morbidity and mortality than their counterparts without diabetes. Worsening glycemic control is associated with increasing risk of CV events and mortality, but glycemic control alone does not appear sufficient to improve CV outcomes. Furthermore, some glucose-lowering drugs have been associated with an increased risk of CV events. As a result, the US Food and Drug Administration (FDA) issued guidance in 2008 for the investigation of CV risk with new diabetes therapies. Numerous CV outcomes trials have since been initiated for drugs in the dipeptidyl peptidase 4 (DPP-4) inhibitors, sodiumglucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 receptor agonist (GLP-1 RA) classes. CV safety has been confirmed for a number of drugs. More recently, CV benefits have been shown for some SGLT-2 inhibitors and GLP-1 RAs. Primary care physicians should consider medications that can lower CV risk alongside favorable efficacy and safety profiles for treatment of patients with T2D at high CV risk.
    • Accession Number:
      0 (Dipeptidyl-Peptidase IV Inhibitors)
      0 (Glucagon-Like Peptide-1 Receptor)
      0 (Hypoglycemic Agents)
    • Publication Date:
      Date Created: 20180619 Date Completed: 20190904 Latest Revision: 20190904
    • Publication Date:
      20240628
    • Accession Number:
      29912999